Kuala lumpur: Trinity, a global leader in life sciences commercialisation solutions, has announced the acquisition of EVERSANA’s advisory services operation in Asia-Pacific and the Middle East (APACME), strengthening its role as a tech-enabled strategic partner to leading pharmaceutical, biotech, and medtech companies.
According to BERNAMA News Agency, the acquisition expands Trinity’s global presence in Singapore, Tokyo, Mumbai, Shanghai, Sydney, and Dubai, following its July opening of its Mexico City office. The acquisition will transition EVERSANA’s regional advisory business to Trinity, deepening its expertise and expanding its on-the-ground presence in a rapidly growing region for life sciences innovation.
Trinity chief executive officer, Leslie Orne, expressed enthusiasm about welcoming EVERSANA’s APACME team to its global family. Orne stated that the acquisition not only strengthens Trinity’s footprint in APACME but also unites two high-performing teams dedicated to delivering real-world impact for clients and the patients they serve.
Orne further added that the integration of EVERSANA’s advisory expertise complements Trinity’s evidence-based consulting and technology-driven analytics, further enabling life sciences companies to achieve commercial and clinical success across every stage of the product lifecycle.
As part of the transaction, Trinity and EVERSANA have entered into a strategic collaboration to continue serving shared clients in the APACME region. EVERSANA will maintain its broader commercialisation services, including compliance, field deployment, and market access solutions, while Trinity takes the lead on advisory and strategic consulting.
Founded nearly 30 years ago, Trinity has grown into a trusted partner for more than 350 global clients, establishing itself as a leader in life sciences advisory and technology solutions. The firm was recently named to Forbes’ Best Management Consulting Firms list and recognized as a Leader in Everest Group’s PEAK Matrix for Life Sciences AI and Analytics.